Human immunodeficiency virus type 1 (HIV-1) infection is a significant global public health problem for which development of an effective prophylactic vaccine remains a high scientific priority. Many concepts for a vaccine are focused on induction of appropriate titers of broadly neutralizing antibodies (bNAbs) against the viral envelope (Env) glycoproteins gp120 and gp41, but no immunogen has yet accomplished this goal in animals or humans. One approach to induction of bNAbs is to design soluble, trimeric mimics of the native viral Env trimer. Here, we describe structural studies by negative-stain electron microscopy of several variants of soluble Env trimers based on the KNH1144 subtype A sequence. These Env trimers are fully cleaved between the gp120 and gp41 components and stabilized by specific amino acid substitutions. We also illustrate the structural consequences of deletion of the V1/V2 and V3 variable loops from gp120 and the membrane-proximal external region (MPER) from gp41. All of these variants adopt a trimeric configuration that appropriately mimics native Env spikes, including the CD4 receptor-binding site and the epitope for the VRC PG04 bNAb. These cleaved, soluble trimer designs can be adapted for use with multiple different env genes for both vaccine and structural studies.T he mature human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein trimer is comprised of three copies of a noncovalently linked gp120/gp41 heterodimer that arises from cleavage of the viral gp160 precursor protein. The env sequence is highly variable as the gene evolves under selective pressures created by several factors, including neutralizing antibodies. The resulting amino acid variability, in addition to an extensively glycosylated surface, creates a formidable barrier for antibody recognition and broad neutralization. Thus, the envelope glycoproteins represent a challenging, moving target for the humoral immune system (1). While broadly neutralizing antibodies (bNAbs) have been isolated from a subset of HIV-1-infected individuals, they play at most a limited role in controlling viral replication as they only arise around 1 to 2 years postinfection (2-5). However, experimental data in animal models suggest that vaccine-induced bNAbs, if present at appropriate titers, would protect people from infection (6-12). Accordingly, many research groups are now trying to design Env-based antigens that might be able to induce bNAbs when used as vaccine immunogens.While the link between the design and structure of an antigen and the resulting immune response is poorly understood, it is important that Env-based immunogens are carefully characterized at the molecular level using a range of biochemical, biophysical, and structural tools (13) in order for such correlations to be made. One line of approach to an Env vaccine involves testing the hypothesis that presentation of a "native" (i.e., trimeric) form of Env to the immune system is important for generation of a suitable immune response, including the induction ...